logo-loader
Silence Therapeutics PLC

Silence Therapeutics Announces Board Change

/**/ link{ color: #0563C1 }visited{ color: #954F72 } .q{size:612.0pt 792.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.q{}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}span.al{font-size:16.0pt;line-height:107%; font-family:"Calibri Light","sans-serif"}p.an{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: 2.5pt; margin-top: 0cm; text-autospace: none}span.ak{font-size:16.0pt;font-family:"Calibri Light","sans-serif"; color:#234060}p.ao{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:2.5pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none}p.ap{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:2.5pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal; text-autospace:none}span.ah{color:black}p.aq{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify; text-autospace: none} p.ar{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 5.85pt; margin-right: 0cm; margin-top: 0cm; text-align: justify; text-autospace: none}table.as{width:460.7pt;margin-left:3.4pt;border-collapse:collapse}tr.aa{height:34.15pt}td.ac{width:297.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:34.15pt}p.at{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:5.85pt;margin-bottom:.0001pt;text-align:justify;line-height:normal; text-autospace:none}td.ab{width:120.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:34.15pt}tr.x{height:19.15pt}td.z{width:297.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:19.15pt}td.y{width:120.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:19.15pt}tr.u{height:26.15pt} td.w{width:297.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:26.15pt}td.v{width:120.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:26.15pt}td.t{width:297.35pt;padding:0cm 5.4pt 0cm 5.4pt}td.s{width:120.15pt;padding:0cm 5.4pt 0cm 5.4pt} /**/
RNS Number : 3512W
Silence Therapeutics PLC
16 April 2019
 

 

Silence Therapeutics Announces Board Change

April 16, 2019

 

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces today that Dr. Andy Richards, CBE, is leaving his role as interim non-executive Chair and a Director of the Company with immediate effect. The Company's previously announced process to appoint a new Chair is ongoing.

 

Dr. David Horn Solomon, Chief Executive Officer, commented: "Andy Richards has served on the Board of Silence since 2016, first as a non-executive director and more recently as interim Chairman. During this time, Andy has been instrumental in a implementing a bold turnaround of Company strategy which has re-energised our drug-development programmes and led us to a point where we are now preparing to commence in-human trials with our lead RNAi candidate SLN124. I would like to thank Andy for his invaluable contribution to the Company and wish him well in his future endeavours."      

 

 

Enquiries:

 

Silence Therapeutics plc

Dr David Horn Solomon, Chief Executive Officer

Dr Rob Quinn, Interim Chief Financial Officer

Tel:  +44 (0)20 3457 6900



Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson

 

Tel:  +44 (0)20 7418 8900

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Angela Gray

[email protected]

 

Tel: +44 (0) 20 3709 5700

US IR

Westwicke Partners

Peter Vozzo

[email protected]

 Tel: +1 (443) 213-0505

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/ 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOALIFVASTIRLIA

Quick facts: Silence Therapeutics PLC

Price: £2.24

Market: AIM
Market Cap: £174.93 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics hails 'transformational' deal with US firm Mallinckrodt

Silence Therapeutics PLC's (LON:SLN) David Solomon discusses the partnership they've struck with US biopharmaceutical firm Mallinckrodt PLC (NYSE: MNK) to develop and commercialise gene silencing treatments for serious diseases. Mallinckrodt will obtain an exclusive worldwide license to...

on 22/7/19

RNS

Additional Listing

1 day, 11 hours ago

Holding(s) in Company

3 weeks, 1 day ago

Additional Listing

4 weeks ago

Additional Listing

4 weeks, 2 days ago

Additional Listing

on 13/8/19

Additional Listing

on 8/8/19